Dr. Schotzinger brings over 20 years of research, development and management experience to the company, where he has raised significant equity capital and moved the company from a seed-stage company to a clinical-stage company. Prior to joining Viamet, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company, where he was responsible for moving the company's lead drug candidate from Phase 1 to Phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.
Dr. Schotzinger received his B.S. in pharmacy from the Ohio State University. He subsequently earned his Ph.D. in pharmacology and medical degree from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to Board Certification in Internal Medicine.
Dr. Cohen brings over 25 years of experience in management and clinical research to Viamet. Prior to joining the company, Dr. Cohen served as Senior Vice President and Global Head, Early Clinical Development and as Chief Medical Officer for Quintiles, Inc. While at Quintiles, he was involved in the oversight of over 200 industry-sponsored clinical trials across numerous therapeutic areas. Prior to Quintiles, Dr. Cohen held positions of increasing responsibility at the NIH National Institute of Allergy and Infectious Diseases.
Dr. Cohen received his B.A. in biochemistry from Brandeis University. He subsequently earned his medical degree from Duke University School of Medicine, completed internal medicine training at The New York Hospital – Cornell Medical Center and fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases. Dr. Cohen has published more than 60 scientific papers and is a Fellow of the Infectious Diseases Society of America.
Dr. Herrmann joined Viamet in November of 2015. He brings over 15 years of marketing, sales, general management business strategy and market access experience to Viamet. Prior to joining Viamet, Dr. Herrmann served as Head of Global Strategy, Commercial Development & Global Marketing for the Vaccines Business Unit of Pfizer Inc., where he was responsible for redefining the global marketing approach of the business unit as well as for the development of an innovative strategic review process of the business aligning it with some of the key trends in global healthcare. Previous to this role, Dr. Herrmann was asked to create a new business model for Pfizer called the Integrated Health Business unit. In this role he evaluated Pfizer’s options to become a healthcare service and solutions provider in a fast changing healthcare environment. He established numerous innovative partnerships with payers, providers and several tech companies in the healthcare industry to develop solutions tackling some of the most significant shortfalls of care for Pain and CNS patients at a global level. In his role as Global Business Lead for the Pain Franchise Dr. Herrmann developed a new and innovative business model for Pfizer’s pain franchise which later led to the creation of the Integrated Health Business unit. Prior to this, he was Vice President of the Regional Brand Cluster for CNS/Pain for Europe, Canada and Australia. In this role he oversaw the implementation of the regional brand team model for CNS/Pain for Pfizer Europe which not only led to significant efficiency gains but also helped to improve the performance of several key brands across Europe such as Lyrica, Celebrex, Aricept and Zeldox. He also was instrumental in ensuring that commercial input was reflected in clinical development programs to ensure future commercial success of pipeline products. Dr. Herrmann started his career with the German Pfizer affiliate where he held several senior leadership roles before taking on European responsibility.
Dr. Herrman holds an M.D. from the Albert-Ludwigs Universität Freiburg. Dr. Herrmann also received a Master of Business Administration degree from the University of San Diego.
Dr. Tavakkol brings over 25 years of experience in pharmaceuticals, consumer healthcare and academia to Viamet, including substantial expertise in the clinical development of novel antifungal products for superficial as well as systemic indications. Prior to joining Viamet, Dr. Tavakkol most recently served as Senior Vice President of Clinical Development & Operations at Topica Pharmaceuticals, Inc., a privately-held, clinical-stage pharmaceutical company. Dr. Tavakkol was previously Project Product Development Team Leader at Merck & Co., overseeing antifungal drug development. Prior to Merck, Dr. Tavakkol served as Senior Director – Dermatology Clinical Research at Schering Plough. In addition, Dr. Tavakkol was previously with Novartis, where he served as Medical Affairs Clinical Director, Dermatology. Dr. Tavakkol has conducted clinical research and published on a range of fungal infections, including onychomycosis, and on the treatment of fungal diseases with drugs such as Lamisil® and Noxafil®.
Dr. Tavakkol received a Ph.D. in bacteriology & virology and a Postgraduate Diploma in infectious diseases, both from The University of Manchester, UK.